首页> 美国卫生研究院文献>Molecular Imaging >Commentary on A Microfluidic Platform to Design Crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for Enhanced MRI
【2h】

Commentary on A Microfluidic Platform to Design Crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for Enhanced MRI

机译:关于设计用于增强MRI的交联透明质酸纳米粒子(cHANP)的微流体平台的评论

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Strategies to enhance the relaxometric properties of gadolinium (Gd)-based contrast agents (CAs) for magnetic resonance imaging (MRI), without the chemical modification of chelates, have recently had a strong impact on the diagnostic field. We have taken advantage of the interaction between Gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) and the hydrogel structure of hyaluronic acid to design cross-linked hyaluronic acid nanoparticles down to 35 nm for use in MRI applications. The proposed bioformulations enable the control of the relaxometric properties of CAs, thus boosting the relaxation rate of T1. Our results led us to identify this approach as an adjustable scenario to design intravascularly injectable hydrogel nanoparticles entrapping Gd-DTPA. This approach overcomes the general drawbacks of clinically approved CAs having poor relaxivity and toxic effects.
机译:最近,在不对螯合物进行化学修饰的情况下,增强用于磁共振成像(MRI)的基于((Gd)的造影剂(CA)的弛豫特性的策略最近对诊断领域产生了重大影响。我们利用Ga二亚乙基三胺五乙酸(Gd-DTPA)与透明质酸的水凝胶结构之间的相互作用来设计可用于MRI应用的低至35 nm的交联透明质酸纳米颗粒。拟议的生物制剂能够控制CA的弛豫特性,从而提高T1的弛豫率。我们的结果使我们将这种方法确定为设计可捕获Gd-DTPA的血管内可注射水凝胶纳米颗粒的可调整方案。该方法克服了临床认可的具有松弛性和毒性作用差的CA的一般缺点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号